Exhaled breath contains chemical clues to what’s going on inside the body, including diseases like lung cancer. And devising ways to sense these compounds could help doctors provide early diagnoses — and improve patients’ prospects. In a study in ACS Sensors, researchers report developing ultrasensitive, nanoscale sensors that in small-scale tests distinguished a key change in the chemistry of the breath of people with lung cancer. November is Lung Cancer Awareness Month.

Sylvain Bouix, from École de technologie supérieure (ÉTS), Martha E. Shenton and Ofer Pasternak, from the Brigham and Women’s Hospital (Harvard University), and René Kahn, from Mount Sinai Hospital (New York) has just received US $33 million in funding—the equivalent of CAD 45 million—over five years from the National Institute of Mental Health to better understand the mechanisms of action of new drugs designed to treat psychosis.

Kidney disease is a global health concern, but conventional tests that check creatinine levels often overlook early signs of damage. To solve this, researchers developed an innovative biosensor that detects symmetric dimethylarginine (SDMA), a byproduct of protein breakdown.  The sensor uses special peptides to measure SDMA in urine with high accuracy and does not need additional diagnostic equipment. This simple, cost-effective tool enables early detection of kidney issues, supporting timely interventions and improved patient outcomes.